Nebulisers for patients with HIV infection and AIDS R F Miller, M J O'Doherty
When nebulisers are used for HIV positive being nausea and rash. Nebulised pentamidine should be offered to those who are intolerant patients and those with AIDS they should, where possible, be used away from other of co-trimoxazole and dapsone/pyrimethamine. immunosuppressed or immunocompetent patients and health care workers because of the risk of droplet spread (by cough) of Mycobacterium tuberculosis and other opportunistic    infections. 1 The choice of nebuliser and delivery system is If nebulisers are to be used within the hospital dictated by the need to deposit pentamidine then nebulisation should be carried out in a in the alveoli and to avoid deposition in the room separate from the main ward area, ideally oropharynx, trachea, and major bronchi. Unwith a separate air extraction system. If nebu-like bronchodilators, nebulised pentamidine lisers are to be used for prophylactic inhalation produces significant local adverse reactions if it of pentamidine then, alternatively, patients deposits in the upper airways, including hypercould be taught how to do this themselves salivation, a metallic or bitter taste, nausea, or with the help of a partner at home and cough, dyspnoea, and bronchoconstriction. [8] [9] [10] appropriate resources should be invested in This makes conventional jet nebulisers inproviding home nebulisers and compressors. appropriate as they produce droplets of many Indications for the use of nebulisers in patients sizes, some of which deposit in the upper reswith HIV infection and AIDS are shown in piratory tract. Very few nebuliser and delivery table 1. systems have been shown, in prospective clinical studies, to deposit adequate quantities of pentamidine in the alveoli and so afford effectNebulised pentamidine for prophylaxis of ive prophylaxis. 5 6 Pneumocystis carinii pneumonia  Primary prophylaxis is indicated if an HIV positive patient has either a CD4 (T helper) cell Respirgard II count of <200/mm 3 (normal range 350-2200/ This is a jet nebuliser which has a series of mm 3 ) or a CD4:total lymphocyte count ratio internal baffles which limit the passage of large below 1:5; 2 or oral thrush or unexplained fever droplets into the aerosol and so reduce the regardless of CD4 count; 3 4 or an alternative frequency of adverse reactions. It also has a AIDS defining diagnosis -for example, on the filter on the exhalation limb which reduces basis of cerebral toxoplasmosis or cutaneous environmental contamination. The aerosol Kaposi's sarcoma regardless of CD4 count. 4 characteristics (measured with a laser beam Secondary prophylaxis should be started after diffraction particle sizer) are mass median aeroan episode of P carinii pneumonia. dynamic diameter (MMAD) = 0.8 m, geoOral co-trimoxazole 960 mg once daily is Division of Pathology metric standard deviation (GSD) = 1.5. 8 The rating" -that is, output does not vary.
London and (1) Prophylaxis of Pneumocystis carinii pneumonia Its advantages are that it has been widely
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pentamidine. The metallic taste and hypersalivation can be minimised if the patient keeps This is a jet nebuliser with a higher mass output than the Respirgard II, but as the aerosol it the nebuliser mouthpiece in the mouth throughout nebulisation and does not remove generates is larger (MMAD = 5 m) there is a higher rate of adverse reactions from upper it to speak; this will also reduce environmental contamination. airways and oropharyngeal deposition of pentamidine. 9 The dose of pentamidine for prophylaxis with this system is 150 mg once per month.
Health care workers Environmental contamination is thought to The adverse reactions can be decreased by using the System 22 Mizer with an Optimist have caused a number of adverse reactions in health care workers administering or superadapter which reduces the MMAD. The intrapulmonary deposition of pentamidine is equi-vising pentamidine nebulisation.
17-19 These have included cough, bronchoconstriction, cirvalent to that with the Respirgard II nebuliser. The system is driven by air or oxygen, or by a cumoral paraesthesiae, a metallic taste in the mouth, 17 18 and progressive reductions of gas continuously rated compressor. Its advantages are that the cost of the nebuliser is less than transfer factor, 19 although this last observation has not been confirmed by other groups. 20 the Respirgard II and the system can be washed out and reused by the same patient. Its disNebulisers with exhalation filters such as the Respirgard II system are less likely to produce advantages are the higher adverse reaction profile which may mean that some patients are environmental contamination than ultrasonic nebulisers. 13 intolerant of pentamidine and require transfer to the Respirgard II system. Nebulisation of pentamidine in hospital or outpatient facilities must be carried out in a room separate from other patients, ideally with its own extraction ventilation system. If nebuFisoNeb This is a small hand held ultrasonic nebuliser lisation is supervised the health care worker (nurse, physiotherapist) should prepare the which produces an aerosol of MMAD 5.2 m and, when loaded with 300 mg pentamidine, nebuliser, load it with pentamidine, and start the compressor (or switch on the air supply), produces equivalent intrapulmonary deposition to a Respirgard II system. However, and then leave the room immediately, not returning until nebulisation is complete. The at this dose the likelihood of adverse reactions of cough, etc is high. In clinical use a dose of patient can be instructed to switch off the air supply or compressor, either if they experience 600 mg pentamidine is used once every two weeks. 12 Its advantages are that it is a small problems or at completion of nebulisation. If these guidelines are followed the likelihood quiet system which is easily cleaned and is reusable. Its disadvantages are the higher rate of of adverse reactions in health care workers is markedly reduced.
17 adverse reactions at doses producing equivalent deposition to the Respirgard II system. It does not contain a filter and so there is a greater likelihood of environmental contamination Treatment of Pneumocystis carinii pneumonia with exhaled pentamidine; approximately 9% of the pentamidine placed in the nebuliser Nebulised pentamidine is effective for mild to moderate severity pneumocystis pneuescapes into the environment. 13 Other ultrasonic nebulisers are not used for nebulisation monia 4 8 14 21 but is now rarely used because other more effective therapies are available such of pentamidine as they are associated with excessive coughing and lower pulmonary de-as oral co-trimoxazole, clindamycin with primaquine, or atovaquone. If nebulised penposition. 14 tamidine is used as treatment it is suggested that it is combined with intravenous pentamidine (4 mg/kg once daily) for the first 3-5 days to General recommendations Patients using pentamidine should be advised ensure that intrapulmonary accumulation of the drug occurs rapidly, and the likelihood not to smoke cigarettes for at least two hours before nebulisation in order to reduce the like-of extrapulmonary pneumocystosis is reduced.
Studies have used the Respirgard II nebuliser lihood of cough. Nebulised pentamidine should be used with caution in patients with asthma. and either 600 mg pentamidine 20 22 or a dose of 8 mg/kg given once daily for 21 days. 8 It may produce a fall in the peak expiratory flow rate (PEFR) and forced expiratory volume As higher doses of pentamidine are used than for prophylaxis the potential for adverse in one second (FEV 1 ) even in those without a history of asthma. 9 15 These falls in ventilatory reactions is higher. 8 Patients again should be advised to avoid cigarette smoking and a nebucapacity due to bronchoconstriction can be prevented by pretreating patients with lised agonist should be given routinely 20 minutes before nebulised pentamidine. It is bronchodilators. 9 15 16 Nebulised terbutaline (10 mg) or salbutamol (5 mg) given 20 minutes important to obtain alveolar deposition of the drug. Although the Respirgard II is the system before nebulised pentamidine are effective.
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Most centres, however, reserve nebulised pro-that has been licensed in the US by the FDA for delivery of nebulised pentamidine as treatphylactic bronchodilators for patients known to be asthmatic, and give in all other cases ment or prophylaxis, any nebuliser with a proven equivalent intrapulmonary deposition 200 g salbutamol or 500 g terbutaline via a metered dose inhaler 10-15 minutes before the is acceptable. However, no other system has
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Miller, O'Doherty been evaluated in clinical studies in patients mimic saliva; they may be thrown away mistakenly by the laboratory and not analysed. 25 with mild to moderately severe pneumocystis pneumonia. The technique of sputum induction is safe and requires no special supervision but in some It is important to note that there is a very slow clinical response to treatment and it may patients nausea and retching may occur (probably secondary to swallowing hypertonic satake from 10 days to two weeks before there is a reduction in fever and any appreciable line). 25 Other patients become dyspnoeic and in some bronchoconstriction occurs. Some improvement in the chest radiograph. 8 There are also concerns that this form of therapy, if patients have unpredictable arterial desaturation during the procedure and this may used to treat pneumocystis pneumonia, may fail to suppress extrapulmonary dissemination persist after the procedure has finished. 27 This desaturation is not related to the baseline arof P carinii. 23 There is also a higher relapse rate following successful treatment with nebulised terial saturation and may occur without associated dyspnoea. Arterial oxygen saturation pentamidine than following treatment with cotrimoxazole.
24
(Sa 2 ) should be monitored with a transcutaneous oximeter throughout the procedure. In addition, care should be taken if other procedures such as exercise testing are performed
Sputum induction
This technique has evolved for the non-invasive immediately after sputum induction because of the risk of persistent desaturation.
27
diagnosis of respiratory infections such as P carinii and other bacterial pneumonias in immunosuppressed patients. As most HIV positive patients with respiratory problems do not Bronchodilator therapy No special equipment is necessary. The same spontaneously expectorate sputum, sputum induction enables deep cough specimens to be codicils apply to the use of nebulisers -that is, where possible these should be used away from obtained. The patient inhales an aerosol of hypertonic (2.7% = 3N) saline which deposits other immunosuppressed patients because of the risk of nosocomial transmission of tuberin peripheral airways and alveoli. This induces a serous response and, because it is hyper-culosis and other infections. In all ventilation procedures involving radiovia the mucociliary escalator to the central airways. The aerosol induces cough. 25 nuclides a closed system should be used. In HIV positive patients and those with AIDS (or Overall the sensitivity of this technique for diagnosis of P carinii and other pathogens is those perceived to be "at risk") single patient use circuits are recommended. The Medic-Aid less than that from bronchoscopy with bronchoalveolar lavage. 25 The technique is and Amersham circuits are appropriate. likely to be more successful if dedicated personnel such as a staff nurse or physiotherapist are trained in the technique. 25 The yield for P Equipment -     carinii from sputum induction is more likely to be successful if there is a high local prevalence (a) Respirgard II (Marquest): UK supplier:
AAH Medical, Unit 20, Broombank Business of pneumocystis. Hall, Ashby Road, Coleorton, Coalville, and other pathogens.) Another reason for avoiding eating just before the procedure is Leicestershire LE67 8GP. Telephone: 01509 634000. that in some patients it can induce nausea and retching.
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A high output ultrasonic nebuliser -for example, the UltraNeb 99m (DeVilbiss) or        DP100 (DP Medical) -should be used as they enable 20-30 ml of hypertonic saline to be (a) UltraNeb 99m (DeVilbiss): DeVilbiss Health Care UK Ltd, Airlinks, Spitfire Way, nebulised over 15-20 minutes. Close laboratory collaboration is necessary. It is important Heston, Middlesex TW5 9MR. Telephone: 0181 756 1133. to assess the adequacy of the specimen obtained -for example, with Papanicolaou stain to check (b) DP100 (DP Medical): Meylan, France. for the presence of alveolar macrophagesconfirming that the specimen originates from the lower respiratory tract. Samples of induced      (a) Medic-Aid: as above. sputum look clear and are colourless and may
